Generic Name and Formulations:
Glycopyrrolate 1mg; dye-free tabs.
Indications for ROBINUL:
Adjunct in peptic ulcer.
1–2mg 2–3 times daily; max 8mg daily.
Glaucoma. Unstable cardiovascular status. Asthma. GI or urinary tract obstruction. Paralytic ileus or intestinal atony. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
Reflux esophagitis. Autonomic neuropathy. Impaired hepatic or renal function. Cardiovascular disease. Tachycardia. Hypertension. Hyperthyroidism. High environmental temperature. Diarrhea. Elderly. Debilitated. Pregnancy (Cat.B). Nursing mothers.
Concomitant antacids may inhibit absorption. Cyclopropane anesthetics may cause arrhythmias. Additive anticholinergic effects with other anticholinergics, narcotic analgesics, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics.
Anticholinergic effects (e.g., dry mouth, blurred vision, constipation).
Inj (vials) Single dose 1mL—25
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|